Abrocitinib and Venetoclax: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Venetoclax
Abrocitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines can interact. Abrocitinib (Cibinqo) can block a transporter called P-gp that normally helps move venetoclax (Venclexta) out of your body. When that transporter is slowed down, more venetoclax can build up in your blood. That can raise your chance of side effects, including a serious problem called tumor lysis syndrome, where cancer cells break down too fast.
The good news is that your care team knows how to handle this. They may lower your venetoclax dose and watch you more closely with lab tests. Please don't stop or change either medicine on your own, just check in with your pharmacist or doctor so they can tailor your plan.
Interaction: Abrocitinib inhibits P-gp, reducing efflux of venetoclax (a P-gp substrate), increasing venetoclax exposure and toxicity risk, including tumor lysis syndrome.
- Direction: Increased venetoclax Cmax/AUC (a reference P-gp inhibitor raised Cmax ~106% and AUC ~78%).
- Evidence: Probable; severity major; onset unspecified.
- Management: If coadministration is required, reduce venetoclax dose by at least 50%. On discontinuation of the P-gp inhibitor, wait 2 to 3 days before resuming the prior venetoclax dose.
- Monitor: TLS labs (potassium, phosphate, uric acid, calcium, renal function) and cytopenias.
What happens
Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome
Interaction Deep Dive
Taking venetoclax together with a P-gp inhibitor can raise venetoclax exposure and heighten the likelihood of venetoclax-related toxicities, among them tumor lysis syndrome. A pharmacokinetic study involving 11 healthy subjects showed that giving venetoclax alongside a single 600 mg dose of rifAMPin (a P-gp inhibitor) raised venetoclax Cmax by 106% and AUC by 78%. Likewise, in drug interaction studies, combining venetoclax with a P-gp inhibitor (such as ritonavir, posaconazole, or ketoconazole) led to markedly higher venetoclax exposure. When venetoclax must be given with a P-gp inhibitor, cut the venetoclax dose by a minimum of 50%. After the P-gp inhibitor is stopped, allow 2 to 3 days to pass before returning to the venetoclax dose that was in use before the inhibitor was started1.
Why it happens (mechanism)
Inhibition of P-gp-mediated efflux transport of venetoclax
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This interaction is manageable.
- Your team may reduce your venetoclax dose (often by at least half) while you are also taking abrocitinib.
- If abrocitinib is stopped, your team may wait 2 to 3 days before returning venetoclax to its earlier dose.
- Expect closer monitoring, including blood tests for tumor lysis syndrome and blood counts.
Ask your pharmacist or prescriber before starting or stopping either drug, and report any new symptoms like nausea, weakness, or reduced urination.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
4 reports — tap to read
a) In a pharmacokinetic study involving 11 healthy participants, giving venetoclax together with a single 600 mg dose of rifAMPin (an inhibitor of OATP1B1/1B3 and P-gp) raised the venetoclax Cmax by 106% and the AUC by 78% 1.
b) Taking ketoconazole (a potent inhibitor of CYP3A, P-gp, and BCRP) at 400 mg once daily over 7 days raised venetoclax Cmax by 130% and AUC(0-inf) by 540% 1.
c) Taking ritonavir (a potent inhibitor of CYP3A, P-gp, and OATP1B1/B3) at 50 mg once daily over 14 days raised venetoclax Cmax by 140% and AUC by 690% 1.
d) Taking posaconazole (a potent inhibitor of CYP3A and P-gp) at 300 mg alongside venetoclax 50 mg and 100 mg for 7 days produced 61% and 86% greater venetoclax Cmax, respectively 1.
Common questions
Can I take Abrocitinib and Venetoclax together?
Abrocitinib can raise venetoclax levels and toxicity risk, so your care team will likely cut the venetoclax dose and monitor you closely. Do not change either medicine on your own; talk with your pharmacist or doctor. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abrocitinib and Venetoclax interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abrocitinib and Venetoclax interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This interaction is manageable. Your team may reduce your venetoclax dose (often by at least half) while you are also taking abrocitinib. If abrocitinib is stopped, your team may wait 2 to 3 days before returning venetoclax to its earlier dose. Expect closer monitoring, including blood tests for tumor lysis syndrom… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Abrocitinib or Venetoclax need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VENCLEXTA(R) oral tablets, venetoclax oral tablets. AbbVie Inc (per FDA), North Chicago, IL, 2022. DailyMed
Keep reading about Venetoclax
Keep reading about Abrocitinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist